The Clorox Company
CLX · NYSE
Company research
The Clorox Company (NYSE: CLX) is a leading American multinational manufacturer and marketer of consumer and professional products, founded in 1913 and headquartered in Oakland, California. Operating through four segments — Health and Wellness, Household, Lifestyle, and International — the company markets an extensive portfolio of well-known brands including Clorox bleach, Pine-Sol, Glad, Hidden Valley, Burt's Bees, Brita, Kingsford, and Fresh Step, with approximately 80% of its brands holding either the number one or number two market share position in their respective retail categories. Under the leadership of CEO Linda J. Rendle, Clorox serves customers across more than 100 markets worldwide through a broad distribution network spanning mass retailers, grocery outlets, warehouse clubs, e-commerce platforms, and direct sales channels, generating approximately $7.1 billion in net sales for fiscal year 2024. With roughly 7,400 full-time employees and a market capitalization of approximately $11.3 billion, Clorox remains a staple in the Consumer Defensive sector, recognized for its brand strength, innovation, and commitment to sustainability.
Research reports
StockStory Analyst Team · June 24, 2026Clorox (CLX) Research Report: Q1 CY2026 Update
StockStory’s Q1 CY2026 update labels CLX “Underperform,” noting flat revenue of 1.67 billion dollars, an adjusted EPS beat to 1.64 dollars but declining gross margins and lowered full‑year EPS guidance, and concludes there are better opportunities than Clorox despite its strong historic ROIC and solid free‑cash‑flow profile.
Sure Dividend · May 11, 2026Clorox Company (CLX)Sure Dividend’s May 11, 2026 report views Clorox as a defensive dividend payer trading below its estimated fair value (111 dollars vs. a 92‑dollar price), projects roughly 5% annual EPS growth and about 12.9% total returns over five years, but maintains a hold rating given ERP‑related costs, logistics and labor headwinds, elevated payout ratio and only moderate confidence in sustained margin expansion.
Actinver Casa De Bolsa (Actinver Análisis) · March 6, 2026CLX Clorox CompanyActinver’s March 6, 2026 equity report sets a 12‑month price target of 135.55 dollars (around 18.22% upside from 114.66), compares CLX’s year‑to‑date gain of 14.98% to a modest S&P 500 decline, reviews its trading range and consensus target of 123.33 dollars, and highlights that most of the 21 covering analysts rate the stock as hold while Actinver sees further upside in this consumer staples name despite prior underperformance and acquisition‑related uncertainties.
Stanley Laman Group · January 18, 2026The Clorox Company (CLX)Stanley Laman’s research note argues that Clorox’s negative shareholders’ equity (down to about minus 22 million dollars) and under‑appreciated technology infrastructure requirements beyond the stated ERP budget will compress free cash flow and keep the dividend payout ratio elevated, and therefore recommends reducing positions on strength and avoiding new purchases until the balance sheet and capital structure are meaningfully repaired.